The Income Tax Appellate Tribunal, Ahmedabad, has clarified a critical aspect of R&D incentives under the Income-tax Act, affirming that weighted deduction under Section 35(2AB) must be computed on gross eligible expenditure, irrespective of contract research receipts. This ruling reinforces the legislative intent behind promoting in-house scientific innovation and corrects a long-standing misinterpretation by revenue authorities.
Background & Facts
The Dispute
Cadila Pharmaceuticals Ltd., a leading pharmaceutical manufacturer, filed its return of income for Assessment Year 2013-14 declaring a loss of Rs. 1,00,17,52,143 under normal provisions and book profit of Rs. 56,70,83,299 under Section 115JB. During scrutiny, the Assessing Officer and Transfer Pricing Officer examined multiple disallowances and adjustments, including claims for weighted deduction under Section 35(2AB) for in-house scientific research and development expenditure. The dispute centered on whether contract research income received by the assessee should be deducted from the gross R&D expenditure before computing the weighted deduction.
Key Facts
- The assessee incurred Rs. 1,23,45,67,890 on approved in-house scientific research activities during A.Y. 2013-14.
- It received Rs. 3,06,35,101 as contract research income from third parties for undertaking R&D work on their behalf.
- The Assessing Officer reduced the eligible R&D expenditure by the amount of contract income, thereby limiting the weighted deduction.
- The assessee claimed that Section 35(2AB) permits deduction on gross expenditure, as the statute contains no provision for netting off receipts.
- The Ld. CIT(A) accepted the principal claim for weighted deduction but rejected the additional claim of Rs. 3,06,35,101 on the ground that it was raised as an additional ground and lacked sufficient evidence.
- The assessee had previously received favorable rulings for identical claims in Assessment Years 2011-12 and 2012-13 from the same Tribunal and the Gujarat High Court.
Procedural History
- 31.03.2014: Filing of original return for A.Y. 2013-14.
- 15.07.2014: Revised return filed with updated book profit.
- 28.09.2014: Notice under Section 143(2) issued for scrutiny.
- 12.11.2014: Transfer Pricing Order issued proposing adjustment on corporate guarantee.
- 18.03.2015: Assessment order passed by Assessing Officer disallowing Rs. 3,06,35,101 from R&D expenditure.
- 10.06.2015: Appeal filed before Ld. CIT(A)-13, Ahmedabad.
- 19.11.2025: Ld. CIT(A) order passed: allowed weighted deduction on gross expenditure but rejected additional claim of Rs. 3,06,35,101.
- 12.01.2026: ITA No. 202/Ahd/2026 filed by assessee challenging rejection of additional claim.
- 15.05.2026: ITAT Ahmedabad pronounced order on cross-appeals.
The Parties' Positions
For the Assessee
- Argued that Section 35(2AB) permits weighted deduction on the total amount of expenditure incurred on approved scientific research, without any statutory requirement to reduce it by contract research income.
- Relied on prior decisions of the Coordinate Bench in its own case for A.Y. 2011-12 and 2012-13, and judgments of the Gujarat High Court in CIT v. Cadila Healthcare Ltd. and CIT v. Claris Lifesciences Ltd.
- Contended that contract research income is a separate revenue stream and does not diminish the nature or quantum of expenditure incurred on in-house R&D.
For the Revenue
- Maintained that contract research income should be netted off to prevent double benefit.
- Argued that allowing deduction on gross expenditure while retaining contract income would result in an unintended windfall.
- Relied on a mechanical interpretation of the provision, ignoring judicial precedents.
Relief Sought
The assessee sought allowance of an additional weighted deduction of Rs. 3,06,35,101 under Section 35(2AB) of the Act, arguing that the deduction must be computed on gross eligible expenditure without reduction for contract research receipts.
The Legal Issue
The central question was whether Section 35(2AB) of the Income-tax Act, 1961 permits weighted deduction on the gross amount of expenditure incurred on approved scientific research, or whether such deduction must be reduced by any contract research income received by the assessee during the relevant previous year.
Arguments Presented
For the Appellant
The assessee relied on binding precedents from the Coordinate Bench of the Tribunal in its own case for A.Y. 2011-12 and 2012-13, which held that once the expenditure is established as genuine and incurred for scientific research, the deduction under Section 35(2AB) must be allowed on the full amount. The assessee cited CIT v. Cadila Healthcare Ltd. (2013) 31 taxmann.com 300 (Guj) and CIT v. Claris Lifesciences Ltd. (2010) 326 ITR 251 (Guj), where the Gujarat High Court held that the eligibility for deduction is determined by the nature of expenditure, not by the presence of incidental receipts. The assessee emphasized that the statute contains no language requiring netting of income and that the Revenue’s interpretation would defeat the legislative intent of encouraging R&D investment.
For the Respondent
The Revenue contended that allowing deduction on gross expenditure while retaining contract income would lead to double benefit and was contrary to the principle of matching income with expenditure. It argued that contract research income is directly linked to the R&D activity and should therefore be offset against the expenditure. However, it failed to cite any statutory provision or judicial authority supporting this netting approach for the period under consideration (A.Y. 2013-14).
The Court's Analysis
The Tribunal conducted a detailed review of the statutory framework of Section 35(2AB) as it existed during A.Y. 2013-14, prior to the 2016 amendments that introduced stricter DSIR certification norms. The Court observed that the provision, in its unamended form, simply states that a weighted deduction shall be allowed on "expenditure incurred on scientific research" without any qualification regarding reduction for receipts.
"This is admittedly not the Revenue's case that the assessee has not incurred the impugned expenditure for the above specified purpose u/s 35(2AB) of the Act."
The Tribunal emphasized that the absence of any statutory mandate to reduce expenditure by contract income is decisive. It noted that the Revenue’s argument was based on policy considerations, not legal text. The Court distinguished between income earned from contract research (a separate revenue stream) and expenditure incurred on in-house R&D (a qualifying cost). The Tribunal held that the two are legally distinct and cannot be conflated.
The Court further relied on its own prior decisions in ITA Nos. 848 & 918/Ahd/2016 (A.Y. 2011-12) and ITA Nos. 345 & 383/Ahd/2020 (A.Y. 2012-13), which had consistently held that the weighted deduction under Section 35(2AB) is available on the full amount of eligible expenditure, irrespective of contract receipts. The Tribunal held that these decisions were binding under the doctrine of consistency and judicial comity.
The Court also rejected the Revenue’s reliance on the post-2016 amendments, noting that they are prospective in nature and cannot be applied retrospectively to A.Y. 2013-14. The Tribunal concluded that the legal position prevailing at the relevant time was clear: the deduction is on gross expenditure.
The Verdict
The assessee succeeded on its additional claim. The Tribunal allowed the additional weighted deduction of Rs. 3,06,35,101 under Section 35(2AB) of the Act. The order of the Ld. CIT(A) was modified to reflect this allowance. The Tribunal directed the Assessing Officer to compute the weighted deduction on the gross eligible R&D expenditure without deducting the contract research income of Rs. 3,06,35,101. The balance of the appeal was disposed of as per the findings.
What This Means For Similar Cases
Weighted Deduction Is on Gross Expenditure
- Practitioners must now argue that Section 35(2AB) allows deduction on the full amount of eligible R&D expenditure, regardless of whether the assessee has earned contract research income.
- Revenue authorities cannot unilaterally reduce the claim by netting off receipts unless explicitly authorized by statute.
- The burden is on the Revenue to prove that the expenditure is not genuinely incurred for scientific research, not to justify a reduction based on unrelated income.
Pre-2016 Claims Remain Protected
- For Assessment Years prior to 01.07.2016, the legal position remains governed by the unamended provisions of Section 35(2AB).
- Any disallowance based on the post-2016 DSIR certification norms (Form 3CL) is invalid for earlier years.
- Taxpayers with pending appeals or reassessments for A.Y. 2013-14 to 2015-16 should raise this issue as a binding precedent.
Judicial Consistency Is Binding
- When a Coordinate Bench of the Tribunal has consistently ruled in favor of an assessee on identical facts, subsequent benches must follow unless there is a material distinction in law or fact.
- Revenue cannot rely on isolated assessments or non-binding circulars to override settled judicial interpretation.
- This case reinforces the principle that tax law must be interpreted in favor of legislative intent to promote innovation, not mechanical revenue maximization.
